Skip to main content

Month: July 2020

Medtronic to Acquire Medicrea

Medtronic Will Become the First Company to Offer an Integrated Solution Including Artificial Intelligence-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted SurgeryDUBLIN and LYON, France, July 15, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF), a pioneer in the transformation of spinal surgery through artificial intelligence, predictive modeling and patient specific implants, today announced that they have entered into a tender offer agreement for the acquisition of all outstanding shares of Medicrea. The friendly voluntary all-cash tender offer will be at a price of €7.00 per Medicrea share (the “Tender Offer”). The Boards of Directors of both companies have unanimously...

Continue reading

Capgemini Press Release // FSCS chooses Capgemini as strategic technology partner to support the acceleration of its digital transformation program

Good morning,Please find below the press release issued today.Best regards,Michele Moore DuhenGlobal PR Manager | Group Marketing & CommunicationsCapgemini Group | LondonTel.: +44 3709 053408Email: Michele.MooreDuhen@capgemini.com_____________________________FSCS chooses Capgemini as strategic technology partner to support the acceleration of its digital transformation programCapgemini in the UK strengthens and expands existing client relationship with new 5-year agreementLondon and Paris, July 15, 2020 – Capgemini today announced that it has been selected as the strategic technology partner for the Financial Services Compensation Scheme (FSCS). Under the five-year new agreement, Capgemini will work with FSCS to drive innovation through the adoption of digital, cloud and application technologies, a key part of its 2020 strategy.Capgemini...

Continue reading

Communiqué de presse Capgemini // L’organisme de compensation des services financiers du Royaume-Uni choisit Capgemini comme partenaire technologique stratégique pour accélérer sa transformation digitale

Bonjour,Vous trouverez ci-après le communiqué de presse diffusé ce jour.Bien cordialement,Florence LièvreGlobal PR Manager | Group Marketing & CommunicationsCapgemini Group | ParisTel.: +33 1 47 54 50 71Email : florence.lievre@capgemini.com_____________________L’organisme de compensation des services financiers du Royaume-Uni choisit Capgemini comme partenaire technologique stratégique pour accélérer sa transformation digitaleCapgemini et le FSCS ont signé un nouveau contrat de cinq ansLondres et Paris, le 15 juillet 2020 – Capgemini annonce avoir été choisi comme partenaire technologique stratégique par le Financial Services Compensation Scheme (FSCS), l’organisme de compensation des services financiers du Royaume-Uni. Dans le cadre de ce nouveau contrat de cinq ans, Capgemini accompagnera le FSCS dans la concrétisation de sa stratégie 2020...

Continue reading

ForFarmers announces strategy 2020-2025 on 15 September 2020

Lochem, 15 July 2020  ForFarmers announces strategy 2020-2025 on 15 September 2020ForFarmers will publish its strategy 2020-2025 on 15 September before opening of the stock exchange. In addition, ForFarmers will organise its Capital Markets Day for invited analysts and investors on the same day. The presentations can be followed by means of a webcast.On 27 March 2020 ForFarmers announced that due to COVID-19, it was postponing the publication of its strategy 2020-2025 and the relating Capital Markets Day from the originally planned date of 12 May 2020, to a date after the publication of the first half-year 2020 results, which is due to take place on 13 August 2020. More information on how to follow the presentation per webcast will be included in the press release about the results of the first half-year 2020. Note to the editor / For...

Continue reading

ForFarmers maakt strategie 2020 – 2025 bekend op 15 september 2020

Lochem, 15 juli 2020                             ForFarmers maakt strategie 2020 – 2025 bekend op 15 september 2020Op 27 maart jl. kondigde ForFarmers aan de bekendmaking van de strategie 2020-2025 en de daaraan gekoppelde Capital Markets Day, welke beide op 12 mei zouden plaatsvinden, vanwege Covid-19 uit te stellen tot na de publicatie (op 13 augustus aanstaande) van de halfjaarcijfers 2020. In het persbericht over de resultaten van het eerste halfjaar 2020 wordt nader aangegeven op welke wijze de presentaties te volgen zullen zijn via een webcast. Noot voor de redactie / Voor meer informatie:Caroline Vogelzang, Directeur Investor RelationsT +31 (0)573 28 81 94 • M +31 (0)6 10 94 91 61 • E: caroline.vogelzang@forfarmers.euForFarmers is met een afzet van 10,1 miljoen ton diervoeders op jaarbasis marktleider in Europa. De onderneming...

Continue reading

Bergman & Beving AB: Interim Report 1 April–30 June 2020

Press releaseInterim Report 1 April–30 June 2020First quarter (1 April–30 June 2020)Revenue increased by 7 percent to MSEK 1,097 (1,024).EBITA increased by 5 percent to MSEK 64 (61).Net profit amounted to MSEK 40 (38).Earnings per share amounted to SEK 1.50 (1.40).Cash flow from operating activities amounted to MSEK 133 (81).The Board proposes a dividend of SEK 1.50 per share (3.00).The COVID-19 pandemic had a variety of effects on operations during the first quarter. Sales of personal protective equipment increased. Construction-related sales improved while industry-related sales were affected negatively, though with some recovery toward the end of the quarter. It is still difficult to determine how significant the impact will be and how long the effects will linger.CEO’s commentsBergman & Beving began the year with an overall positive...

Continue reading

Bergman & Beving AB: Delårsrapport 1 april – 30 juni 2020

PressmeddelandeDelårsrapport 1 april – 30 juni 2020Första kvartalet (1 april – 30 juni 2020)Nettoomsättningen ökade med 7 procent och uppgick till 1 097 MSEK (1 024).Resultatet (EBITA) ökade med 5 procent och uppgick till 64 MSEK (61).Resultatet efter skatt uppgick till 40 MSEK (38).Resultat per aktie uppgick till 1,50 SEK (1,40).Kassaflödet från den löpande verksamheten uppgick till 133 (81).Styrelsen föreslår en utdelning om 1,50 SEK per aktie (3,00).Covid-19-pandemin påverkade verksamheten på olika sätt under det första kvartalet. Försäljningen av personlig skyddsutrustning ökade. Byggrelaterad försäljning stärktes medan industrirelaterad försäljning påverkades negativt med viss återhämtning i slutet av kvartalet. Det är fortsatt svårt att bedöma hur stor påverkan blir och hur länge effekterna består.VD:s kommentarerBergman &...

Continue reading

Eurobio Scientific expands into Switzerland, Germany, Austria and Benelux by acquiring the diagnostic company TECOmedical AG

Eurobio Scientific expands into Switzerland, Germany, Austria and Benelux by acquiring the diagnostic company TECOmedical AGParis, July 15, 2020 –7:30 amEurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, announces the acquisition of 100% of the share capital of TECOmedical AG (“TECO”), parent company of a Swiss group specializing in the development and distribution of in vitro diagnostic tests in Europe, with operations in Switzerland, Germany, Austria and Benelux. The acquisition, which financial terms are not disclosed, was paid in cash.A strong reputation in specialty tests for medical diagnosticsFounded in 1984, TECO is based in Sissach, Switzerland. The company offers a range of specialty biomarker assays under exclusive distribution contracts,...

Continue reading

Eurobio Scientific s’implante en Suisse, en Allemagne, en Autriche et au Benelux via l’acquisition de la société de diagnostic TECOmedical AG

Eurobio Scientific s’implante en Suisse, en Allemagne, en Autriche et au Benelux via l’acquisition de la société de diagnostic TECOmedical AGParis, le 15 juillet 2020 – 7h30Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce l’acquisition de 100% du capital de TECOmedical AG (“TECO”), société mère d’un groupe suisse spécialisé dans le développement et la distribution de tests de diagnostic in vitro en Europe, présent en Suisse, en Allemagne, en Autriche et au Benelux. L’acquisition, dont les conditions financières ne sont pas communiquées, a été payée en numéraire.Une solide réputation dans les tests de spécialités pour le diagnostic médicalCréée en 1984, TECO est basée à Sissach, en Suisse. La société propose une gamme...

Continue reading

Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific

Basel, Switzerland, July 15, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its license partner, Pfizer Inc. (NYSE: PFE, “Pfizer”), has launched the antifungal Cresemba® (isavuconazole) in Taiwan. The launch triggered the second milestone payment (USD 0.5 million) related to the Asia-Pacific territory from Pfizer to Basilea.David Veitch, Chief Executive Officer, said: “We are very pleased with the launch of Cresemba in Taiwan, which triggers the second launch milestone payment related to the Asia-Pacific region and follows the launch in Australia earlier this year. We are glad we can now bring Cresemba to patients in Taiwan and we are looking forward to our partner Pfizer making Cresemba more broadly available in the region, for the benefit of patients suffering from invasive mold infections.”In Taiwan, Cresemba...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.